Familial erythrocytosis

Familial erythrocytosis: Description, Causes and Risk Factors: Familial erythrocytosisErythrocytosis is a rare red cell disorder that can arise from diverse molecular origins. It is characterized by an elevated hematocrit and hemoglobin level. There is no accompanying increase in the number of white cells or platelets. Both sporadic and familial forms exist and age of presentation is highly variable. Individuals with erythrocytosis exhibit a wide range of serum Epo (erythropoietin) levels and this reflects the heterogeneity of this disorder. Erythrocytosis can be further classified as either primary or secondary depending on whether the defect is intrinsic or extrinsic to the erythroid progenitor cells. In primary erythrocytosis the serum Epo level is subnormal and the erythroid progenitors are hypersensitive to Epo, which suggests the defect lies in the Epo-induced signaling pathway. Secondary erythrocytosis is associated with inappropriately normal or raised serum Epo levels indicating a defect in the control of Epo synthesis by the oxygen-sensing pathway. Both reflect our current understanding of how red blood cell mass is regulated. Familial erythrocytosis is an inherited condition characterized by an increased number of red blood cells (erythrocytes). The primary function of these cells is to carry oxygen from the lungs to tissues and organs throughout the body. Signs and symptoms of familial erythrocytosis can include headaches, dizziness, nosebleeds, and shortness of breath. The excess red blood cells also increase the risk of developing abnormal blood clots that can block the flow of blood through arteries and veins. If these clots restrict blood flow to essential organs and tissues (particularly the heart, lungs, or brain), they can cause life-threatening complications such as a heart attack or stroke. However, many people with familial erythrocytosis experience only mild signs and symptoms or never have any problems related to their extra red blood cells. Familial erythrocytosis can result from mutations in the EPOR, VHL, EGLN1, or EPAS1 gene. Researchers define four types of familial erythrocytosis, ECYT1 through ECYT4, based on which of these genes is altered. The EPOR gene provides instructions for making a protein known as the erythropoietin receptor, which is found on the surface of certain blood-forming cells in the bone marrow. Erythropoietin is a hormone that directs the production of new red blood cells. Erythropoietin fits into the receptor like a key into a lock, triggering signaling pathways that lead to the formation of red blood cells. Mutations in the EPOR gene cause the erythropoietin receptor to be turned on for an abnormally long time after attaching to erythropoietin. The overactive receptor signals the production of red blood cells even when they are not needed, which results in an excess of these cells in the bloodstream. When familial erythrocytosis is caused by mutations in the EPOR gene, it is known as ECYT1. The proteins produced from the VHL, EGLN1, and EPAS1 genes are also involved in red blood cell production; they each play a role in regulating erythropoietin. The protein produced from the EPAS1 gene is one component of a protein complex called hypoxia-inducible factor (HIF). When oxygen levels are lower than normal (hypoxia), HIF activates genes that help the body adapt, including the gene that provides instructions for making erythropoietin. Erythropoietin stimulates the production of more red blood cells to carry oxygen to organs and tissues. The proteins produced from the VHL and EGLN1 genes indirectly regulate erythropoietin by controlling the amount of available HIF. Mutations in any of these three genes can disrupt the regulation of red blood cell formation, leading to an overproduction of these cells. When familial erythrocytosis results from VHL gene mutations it is known as ECYT2; when the condition is caused by EGLN1 gene mutations it is called ECYT3; and when the condition results from EPAS1 gene mutations it is known as ECYT4. Researchers have also described non-familial (acquired) forms of erythrocytosis. Causes of acquired erythrocytosis include long-term exposure to high altitude, chronic lung or heart disease, episodes in which breathing slows or stops for short periods during sleep (sleep apnea), and certain types of tumors. Another form of acquired erythrocytosis, called polycythemia vera, results from somatic (non-inherited) mutations in other genes involved in red blood cell production. In some cases, the cause of erythrocytosis is unknown. Symptoms: Whatever the cause of erythrocytosis, symptoms may not be apparent in the early stages and the condition may be discovered from routine blood tests. Vague symptoms such as tiredness may be present and sometimes sweating, itching, dizziness and headaches may be experienced. For people who have polycythemia vera, there is an increased risk of blood clots occurring and in some cases the first sign of the condition may be a thrombosis, or clot, inside a blood vessel, causing a problem such as a stroke or heart attack. Diagnosis: Stage I diagnosis: Full blood count/?lm.
  • Arterial oxygen saturation.
  • Ferritin level.
  • Renal and liver function tests.
  • Abdominal ultrasound.
  • Serum erythropoietin level.
  • Chest X-ray.
Stage II diagnosis: Bone marrow aspirate/trephine.
  • Cytogenetics.
  • BFU-E culture.
  • Oxygen dissociation curve (p50).
  • Sleep study.
  • Lung function tests.
  • Erythropoietin receptor gene analysis.
  • VHL analysis.
Treatment: The treatment of erythrocytosis depends on the cause. Secondary forms of the condition require treatment of the underlying disorder, and the outlook will depend on how successful this is. In the case of a long-term lung disease, giving oxygen may help reduce the levels of erythropoietin and decrease red blood cell numbers. For the primary condition, if the rare blood disease polycythemia vera is the cause, the outlook is poor without treatment. There is a high risk of a fatal stroke or heart attack occurring within 18 months. With treatment, the outlook improves to give an estimated Life expectancy of around 20 years. NOTE: The above information is educational purpose. The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. DISCLAIMER: This information should not substitute for seeking responsible, professional medical care.

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

Cart Preview

Flavonoids in Fruits and Vegetables May Preserve Lung Function

Flavonoids in Fruits and Vegetables May Preserve Lung Function

A new study from the US discovers that flavonoids, natural compounds found in fruits and vegetables, may help preserve the lung function, which tends to decline with age. For the study, a team of researchers looked at data from 463 adults from Norway and England whose...

Regular Exercising May Keep Your Heart and Main Arteries Young

Regular Exercising May Keep Your Heart and Main Arteries Young

According to a recent study, published in The Journal of Physiology, exercising four to five times per week may help stop the main arteries to the heart from stiffening up. The researchers from the US have found that those who exercise four to five times per week had...

Quiz about this article

Please answer on few questions to make our service more useful

Featured Products

Spring is Here: Top 6 Outdoor Sports

Good weather is the best reason to do outdoor sports, which will help not only lose weight, but also will strengthen health. Bicycle The sun dries out the local paths, so you can safely sit on your favorite bike and confidently twist the pedals, where the eyes look....

read more

First Aid in Case of Injuries for Sport and Exercise

First aid for injuries consists of simple rules that need to be clearly implemented. If this is a closed injury, you need to immobilize the injured limb, otherwise the person may lose consciousness from a painful shock. If you need to get to the emergency room...

read more